Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares on May 8 at an average price of $564.95, totaling about $5.37 million. After the sale, Rothblatt still held 40,513 shares, reducing ownership by 19%.
- The company recently reported earnings below expectations, posting $5.82 EPS versus the $7.00 consensus estimate and revenue of $781.5 million, slightly under forecasts. Revenue also declined 1.6% year over year.
- Analysts remain broadly positive on UTHR, with 11 Buy ratings and 2 Hold ratings, and a consensus “Moderate Buy” rating. The average price target stands at $619.42, above the stock’s recent trading level.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $564.95, for a total transaction of $5,367,025.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at $22,887,819.35. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics Price Performance
UTHR stock opened at $569.88 on Tuesday. The company's 50 day simple moving average is $552.09 and its 200-day simple moving average is $503.34. The firm has a market capitalization of $24.19 billion, a PE ratio of 21.04, a P/E/G ratio of 1.80 and a beta of 0.60. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm's revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.63 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 27.4 earnings per share for the current year.
Institutional Trading of United Therapeutics
A number of hedge funds have recently bought and sold shares of the company. Avoro Capital Advisors LLC boosted its position in United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the last quarter. Wellington Management Group LLP boosted its position in United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the last quarter. AQR Capital Management LLC boosted its position in United Therapeutics by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock worth $624,508,000 after acquiring an additional 295,221 shares during the last quarter. Janus Henderson Group PLC boosted its position in United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company's stock worth $387,801,000 after acquiring an additional 341,383 shares during the last quarter. Finally, Darwin Global Management Ltd. acquired a new stake in United Therapeutics during the third quarter worth approximately $317,617,000. Institutional investors and hedge funds own 94.08% of the company's stock.
Analyst Ratings Changes
Several analysts have recently commented on the stock. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an "overweight" rating in a research report on Thursday, March 12th. Raymond James Financial assumed coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an "outperform" rating and a $700.00 price target on the stock. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research report on Thursday. Bank of America increased their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a "neutral" rating in a research report on Tuesday, March 31st. Finally, HC Wainwright raised their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research report on Tuesday, March 31st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $619.42.
Read Our Latest Stock Analysis on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
